JP2011519846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519846A5 JP2011519846A5 JP2011506766A JP2011506766A JP2011519846A5 JP 2011519846 A5 JP2011519846 A5 JP 2011519846A5 JP 2011506766 A JP2011506766 A JP 2011506766A JP 2011506766 A JP2011506766 A JP 2011506766A JP 2011519846 A5 JP2011519846 A5 JP 2011519846A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- testosterone
- ethanol
- lauroglycol
- sesame oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 14
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 11
- 229960003604 testosterone Drugs 0.000 claims 9
- 235000019445 benzyl alcohol Nutrition 0.000 claims 4
- 239000008159 sesame oil Substances 0.000 claims 4
- 235000011803 sesame oil Nutrition 0.000 claims 4
- -1 lauroglycol Substances 0.000 claims 3
- 238000009165 androgen replacement therapy Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000003585 eunuchism Diseases 0.000 claims 1
- 208000037106 male hypogonadism Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0807605.1A GB0807605D0 (en) | 2008-04-28 | 2008-04-28 | Lipid composition |
| GB0807605.1 | 2008-04-28 | ||
| PCT/GB2009/001068 WO2009133352A2 (en) | 2008-04-28 | 2009-04-27 | Lipid composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011519846A JP2011519846A (ja) | 2011-07-14 |
| JP2011519846A5 true JP2011519846A5 (enExample) | 2012-06-14 |
| JP5727925B2 JP5727925B2 (ja) | 2015-06-03 |
Family
ID=39522593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506766A Active JP5727925B2 (ja) | 2008-04-28 | 2009-04-27 | 脂質組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9012436B2 (enExample) |
| EP (2) | EP2722038A3 (enExample) |
| JP (1) | JP5727925B2 (enExample) |
| KR (1) | KR101617811B1 (enExample) |
| CN (1) | CN102083421B (enExample) |
| AU (1) | AU2009241910B2 (enExample) |
| CA (1) | CA2722408C (enExample) |
| DK (1) | DK2273984T3 (enExample) |
| ES (1) | ES2502242T3 (enExample) |
| GB (1) | GB0807605D0 (enExample) |
| IL (2) | IL208612A (enExample) |
| PL (1) | PL2273984T3 (enExample) |
| PT (1) | PT2273984E (enExample) |
| WO (1) | WO2009133352A2 (enExample) |
| ZA (1) | ZA201007612B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
| US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| EP1871384A4 (en) | 2005-04-15 | 2012-01-25 | Clarus Therapeutics Inc | SYSTEMS FOR THE PHARMACEUTICAL ADMINISTRATION OF HYDROPHOUS ACTIVE SUBSTANCES AND COMPOSITIONS THEREWITH |
| US8861813B2 (en) * | 2008-03-13 | 2014-10-14 | Mallinckrodt Llc | Multi-function, foot-activated controller for imaging system |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
| KR20190117803A (ko) * | 2011-05-15 | 2019-10-16 | 에이세러스 파마슈티칼즈 에스알엘 | 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 |
| ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2014057522A1 (en) | 2012-10-12 | 2014-04-17 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| EP2934591B1 (en) | 2012-12-20 | 2017-08-09 | Solural Pharma Aps | Solid oral dosage form of testosterone derivative |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| WO2014142364A2 (en) | 2013-03-15 | 2014-09-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| KR101440726B1 (ko) * | 2013-04-16 | 2014-09-18 | 중앙대학교 산학협력단 | 가용화제를 포함하는 림프계 약물전달 시스템용 조성물 |
| EP3054940B1 (en) * | 2013-10-07 | 2020-09-23 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
| AU2015276202B2 (en) | 2014-06-19 | 2020-09-17 | Pebean Pharma Aps | Solid oral dosage form of lipophilic compounds |
| MX2016013693A (es) | 2014-07-29 | 2017-10-31 | Therapeuticsmd Inc | Crema transdermica. |
| ES2877107T3 (es) * | 2014-08-28 | 2021-11-16 | Univ Texas | Formulaciones de testosterona y procedimientos de tratamiento con ellas |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR101679380B1 (ko) * | 2015-09-10 | 2016-11-25 | 주식회사 유유제약 | 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형 |
| CN106562949A (zh) * | 2015-10-10 | 2017-04-19 | 浙江旭晨医药科技有限公司 | 甘油三酯类化合物在制备治疗多囊卵巢综合征药物中的应用 |
| CA3016542A1 (en) * | 2016-03-02 | 2017-09-08 | Board Of Regents, The University Of Texas System | Formulations of testosterone and methods of treatment therewith |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| WO2019046582A1 (en) * | 2017-08-30 | 2019-03-07 | Antares Pharma, Inc. | TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS |
| US11311554B2 (en) | 2018-04-04 | 2022-04-26 | Slayback Pharma Llc | Pharmaceutical compositions of testosterone |
| EP3824296A4 (en) | 2018-07-20 | 2022-04-27 | Lipocine Inc. | LIVER DISEASE |
| CN114617968B (zh) * | 2019-04-09 | 2023-10-03 | 北京五和博澳药业股份有限公司 | 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途 |
| JP7822939B2 (ja) * | 2020-02-05 | 2026-03-03 | ニューロクライン ユーケー リミテッド | テストステロン含有医薬組成物 |
| WO2024014958A2 (en) * | 2022-07-15 | 2024-01-18 | Seranovo Holding B.V. | Lides formulation platform |
| WO2024014959A2 (en) * | 2022-07-15 | 2024-01-18 | Seranovo Holding B.V. | Micelle-generating formulations with improved hydrophobicity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4098802A (en) * | 1975-02-18 | 1978-07-04 | Akzona Incorporated | Oral pharmaceutical preparation having androgenic activity |
| GB1567515A (en) | 1976-05-28 | 1980-05-14 | Akzo Nv | Esters of testo-sterone and 5 -dihydro-testosterone |
| NL7711916A (nl) | 1977-10-29 | 1979-05-02 | Akzo Nv | Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden. |
| GB9608719D0 (en) * | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| US6652880B1 (en) * | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
| GB9907715D0 (en) | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
| US6541025B1 (en) | 1999-12-30 | 2003-04-01 | Shear/Kershman Laboratories, Inc. | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| EP1260225A1 (en) * | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| JO2505B1 (en) | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| US7138389B2 (en) * | 2004-02-09 | 2006-11-21 | University Of Washington | Oral androgen therapy using modulators of testosterone bioavailability |
| EP1871384A4 (en) | 2005-04-15 | 2012-01-25 | Clarus Therapeutics Inc | SYSTEMS FOR THE PHARMACEUTICAL ADMINISTRATION OF HYDROPHOUS ACTIVE SUBSTANCES AND COMPOSITIONS THEREWITH |
-
2008
- 2008-04-28 GB GBGB0807605.1A patent/GB0807605D0/en not_active Ceased
-
2009
- 2009-04-27 CN CN2009801149913A patent/CN102083421B/zh active Active
- 2009-04-27 JP JP2011506766A patent/JP5727925B2/ja active Active
- 2009-04-27 WO PCT/GB2009/001068 patent/WO2009133352A2/en not_active Ceased
- 2009-04-27 AU AU2009241910A patent/AU2009241910B2/en active Active
- 2009-04-27 EP EP13186572.7A patent/EP2722038A3/en not_active Withdrawn
- 2009-04-27 PL PL09738382T patent/PL2273984T3/pl unknown
- 2009-04-27 ES ES09738382.2T patent/ES2502242T3/es active Active
- 2009-04-27 PT PT97383822T patent/PT2273984E/pt unknown
- 2009-04-27 CA CA2722408A patent/CA2722408C/en active Active
- 2009-04-27 EP EP09738382.2A patent/EP2273984B1/en active Active
- 2009-04-27 US US12/989,948 patent/US9012436B2/en active Active
- 2009-04-27 KR KR1020107025087A patent/KR101617811B1/ko active Active
- 2009-04-27 DK DK09738382.2T patent/DK2273984T3/da active
-
2010
- 2010-10-11 IL IL208612A patent/IL208612A/en active IP Right Grant
- 2010-10-25 ZA ZA2010/07612A patent/ZA201007612B/en unknown
-
2014
- 2014-12-22 IL IL236400A patent/IL236400A/en active IP Right Grant
-
2015
- 2015-01-21 US US14/601,839 patent/US20150133417A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519846A5 (enExample) | ||
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| IL209121A (en) | Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases | |
| NZ595467A (en) | Sublingual pharmaceutical composition comprising a neutral oil | |
| IL203747A (en) | Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it | |
| MX2011012122A (es) | Derivados de tiofeno. | |
| EA201290982A1 (ru) | Фармацевтические композиции, препятствующие злоупотреблению | |
| CY1118099T1 (el) | Δισκια οξεικης ουλιπρισταλης | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
| MX2011011829A (es) | Composicion para suministro sostenido de farmaco que comprende un aglutinante geopolimerico. | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| JP2010132695A5 (enExample) | ||
| IL233677A (en) | Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition | |
| GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| CL2012000248A1 (es) | Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina. | |
| IL207546A0 (en) | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases | |
| WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
| MX2011002065A (es) | Composicion farmaceutica a base de progesterona micronizada y sus usos. | |
| JP2012517449A5 (enExample) | ||
| NZ595046A (en) | Compositions and methods for extended therapy with aminopyridines | |
| UA104148C2 (ru) | [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1h-индол-3-ил]-метанон как ингибитор триптазы тучных клеток | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| MX2009013501A (es) | Compuestos piperidinicos y sus usos. |